InvestorsHub Logo
Followers 840
Posts 120470
Boards Moderated 18
Alias Born 09/05/2002

Re: DewDiligence post# 928

Tuesday, 06/02/2020 11:02:06 AM

Tuesday, June 02, 2020 11:02:06 AM

Post# of 1168
Zeposia hits primary/secondary endpoints in UC phase-3:

https://www.businesswire.com/news/home/20200602005291/en

-Bristol Myers Squibb (NYSE:BMY) today announced results from True North, a pivotal Phase 3 trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy for adult patients with moderate to severe ulcerative colitis. True North met both primary endpoints, demonstrating highly statistically significant (p-value < 0.0001) results for induction of clinical remission at Week 10 and in maintenance at Week 52. The study also met key secondary endpoints of clinical response and endoscopic improvement in induction at Week 10 and in maintenance at Week 52.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News